Company intelligence / Profile preview

Pelthos Pharmaceuticals

Durham, North Carolina, United States

Ownership: Private
Employees: ~90
Development stage: Other

Overview

Pelthos Therapeutics has successfully commercialized ZELSUVMI (berdazimer), the first and only FDA-approved at-home topical treatment for molluscum contagiosum approved in 2024. The product launched on July 10, 2025, and has received strong physician response with orders and prescriptions meeting or exceeding sales expectations. The company recently acquired XEPI (ozenoxacin) for impetigo treatment, planned for re-launch in late 2026.

Therapeutic areas: OphthalmologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Ligand Pharmaceuticals

Beyond the preview

Go deeper on Pelthos Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelthos Pharmaceuticals.

Explore the full profile